Associations of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use with Colorectal Cancer Risk in the Women's Health Initiative.
Theodore M BraskyKatrina F FloresJoseph C LarsonAlison M NewtonAladdin H ShadyabJonathan H WatanabeDorothy S LaneCynthia A ThomsonAndrea Z LaCroixPublished in: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (2021)
Choice of drug in the large population of aging women who will be prescribed ACEi and ARB should be made without factoring in any benefit on colorectal cancer risk.
Keyphrases
- angiotensin converting enzyme
- angiotensin ii
- polycystic ovary syndrome
- pregnancy outcomes
- healthcare
- public health
- breast cancer risk
- mental health
- cervical cancer screening
- quality improvement
- insulin resistance
- health information
- metabolic syndrome
- adipose tissue
- risk assessment
- climate change
- health promotion
- adverse drug
- electronic health record